We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

65 hedge funds and large institutions have $505M invested in Terns Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

277% more capital invested

Capital invested by funds: $134M → $505M (+$371M)

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

64% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 14

44% more funds holding

Funds holding: 45 → 65 (+20)

23.14% more ownership

Funds ownership: 80.54% → 103.68% (+23%)

Holders
65
Holders Change
+20
Holders Change %
+44.44%
% of All Funds
1.04%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
25
Increased
23
Reduced
14
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$48.4M
2
SCM
Suvretta Capital Management
New York
+$23M
3
Millennium Management
Millennium Management
New York
+$7.15M
4
RI
RTW Investments
New York
+$6.66M
5
DM
Deerfield Management
New York
+$6.6M

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$1.21M
2
IC
Ikarian Capital
Texas
-$1.11M
3
Barclays
Barclays
United Kingdom
-$948K
4
PVI
Pura Vida Investments
New York
-$822K
5
SB
Samsara BioCapital
California
-$577K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.81M +$58.6K +8,800 +5%
ECM
27
Endurant Capital Management
California
$1.38M +$905K +135,994 New
EI
28
EAM Investors
California
$1.3M +$853K +128,186 New
BFM
29
Boothbay Fund Management
New York
$1.28M -$65.5K -9,837 -7%
MIM
30
Monashee Investment Management
Massachusetts
$1.25M +$815K +122,500 New
Renaissance Technologies
31
Renaissance Technologies
New York
$1.17M -$248K -37,300 -25%
PAMP
32
Polar Asset Management Partners
Ontario, Canada
$1.02M +$666K +100,000 New
BCM
33
Bridgeway Capital Management
Texas
$944K +$154K +23,200 +33%
HS
34
HighVista Strategies
Massachusetts
$787K – – –
Walleye Capital
35
Walleye Capital
New York
$749K +$409K +61,487 +507%
ACM
36
Altium Capital Management
New York
$713K +$466K +70,000 New
State Street
37
State Street
Massachusetts
$606K +$116K +17,500 +42%
Citigroup
38
Citigroup
New York
$469K +$302K +45,347 +6,469%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$388K +$254K +38,102 New
Marshall Wace
40
Marshall Wace
United Kingdom
$367K +$240K +36,081 New
HF
41
HRT Financial
New York
$357K +$234K +35,090 New
Northern Trust
42
Northern Trust
Illinois
$322K +$67.2K +10,089 +47%
6CM
43
683 Capital Management
New York
$285K +$186K +28,000 New
AA
44
ALPS Advisors
Colorado
$260K +$170K +25,525 New
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
$229K +$66.4K +9,972 +79%
Jane Street
46
Jane Street
New York
$219K +$54.9K +8,252 +62%
CCM
47
CAAS Capital Management
New York
$204K -$438K -65,851 -77%
Morgan Stanley
48
Morgan Stanley
New York
$184K +$72K +10,815 +149%
DTL
49
Dynamic Technology Lab
Singapore
$160K +$105K +15,709 New
CF
50
Crosspoint Financial
California
$153K +$100K +15,054 New
1
2
3

TERN Hedge Fund Activity: Q4 2022 in Review

65 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q4 2022, worth a combined $505M — up 277% from $134M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TERN positions and 5 closed out — a net gain of 20 holders — while 23 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $48.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $1.21M sold.

  • 65 institutional investors held Terns Pharmaceuticals (TERN) as of Q4 2022, up from 45 in Q3 2022.
  • Funds reported $505M of Terns Pharmaceuticals stock for Q4 2022, up 277% quarter-over-quarter.
  • 25 funds opened new Terns Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of +20 holders.
  • The largest Terns Pharmaceuticals buyer in Q4 2022 was Fidelity Investments, an estimated $48.4M added.
  • The largest Terns Pharmaceuticals seller in Q4 2022 was Commodore Capital, an estimated $1.21M sold.

Based on aggregated 13F filings for Q4 2022.